| Faculty Member | Research Summary |
| Arpana Agrawal, PhD | 1) Genetics of cannabis involvement using epidemiological and genomic methods; 2) G x E models for substance-related outcomes; 3) Comorbidity between substance use and mental illness; 4) Methodology; |
| Andrey Anokhin, PhD | 1) genetic variation in human brain function; 2) neurobehavioral endophenotypes for psychiatric disorders; 3) causes and consequences of underage substance abuse; |
| Laura Jean Bierut, MD | 1) genetic studies of psychiatric illnesses; 2) genetic studies of substance dependence; |
| Kevin J. Black, MD | 1) neuroimaging; 2) Tourette Syndrome; 3) neuropsychiatry of movement disorders; 4) clinical neuropsychiatry; |
| Kelly N. Botteron, MD | 1) Magnetic Resonance Imaging (MRI) studies of child and adolescent affective and attentional disorders; 2) MRI of very early brain development in infants at risk for autism; 3) MRI studies of normal brain development; 4) imaging studies in twin populations; 5) genetics of brain structure and structural correlates of neuropsychiatric disorder; 6) development/implementation of image analysis methods for neuromorphometric analysis of MRI; |
| Kathleen Keenan Bucholz, PhD | 1) PI on a longitudinal family study of alcoholism, with an over sample of African American families, to investigate 3 major developmental models of alcoholism and determine their applicability to AA families (MOFAM). ; 2) PI on a project studying Adolescent and young adult offspring of twin fathers with and without drug/alcohol problems, to investigate genetic and environmental interactions for the offspring own development of drug use and problems, and other psychopa; 3) Co-investigator on offspring-of-alcoholic twins studies to study gene-environment influences on the development of alcoholism, and Co-investigator on gene-environment study of alcoholism (GENEVA), using COGA, FSCD and COGEND sample.; 4) Investigator on a multi-site family study of alcohol dependence (COGA), including baseline and follow up interviews with detailed phenotyping and family history information on children, adolescents, and adults from over 1500 families. ; 5) Co-Director of the Midwest Alcoholism Research Center, with a focus on the etiology and progression of alcohol problems and dependence in youthful populations ; 6) Co-investigator on studies collecting longitudinal data on psychopathology (with an emphasis on alcoholism) in adult Australian twins, their spouses, and offspring.; 7) 11 year follow up study of 753 participants in the St. Louis ECA who were at high risk of alcohol dependence were interviewed, with risk and protective factors obtained at re-interview.; 8) 14 year follow up of 444 participants in the St. Louis ECA, to obtain information about their use and costs of health services, using both self-report (interview) and abstraction of medical records. ; |
| Robert M. Carney, PhD | 1) the significance of psychiatric and psychosocial factors in patients with heart disease; 2) cognitive-behavioral treatment of anxiety and affective disorders; 3) psychiatric comorbidity in medical patients; |
| Theodore J. Cicero, PhD | 1) gender differences in the actions and abuse liability of substances of abuse, particularly morphine and cocaine; 2) basic investigations of the role of endogenous opioid peptides in neuroendocrinology; |
| C. Robert Cloninger, MD | 1) genetic epidemiology of neuropsychiatric disorders; 2) nosology of psychiatric disorders; 3) neurogenetic adaptive processes in personality and psychopathology; |
| John N. Constantino, MD | 1) the influence of genetic and environmental influences on early social development; 2) prevention of antisocial behavior and violence; 3) longitudinal research on the life course and genetic structure of autistic social impairment; 4) in depth study of the intergenerational transmissions of attachment; 5) development of a manulized curriculum for promoting parent-infant attachment; 6) analysis of the association between monoamine neurotransmitters and child behavior; 7) publication of a quantitative measure of autistic traits, the Social Responsiveness Scale ; 8) early intervention program for the prevention of child maltreatment; |
| Elise Fallucco, MD | 1) Educating Primary Care Physicians to Assess Suicide Risk in Adolescents; 2) Educating PCPs to assess Adolescent Depression and Suicide Risk; |
| Nuri B. Farber, MD | 1) pharmacological, neuroanatomical, histochemical, and cognitive/behavioral evaluation of neurodegeneration; 2) glutamate, GABA receptors; 3) psychotic disorders; 4) Alzheimer's disease; 5) developmental disorders; 6) glucocorticoids; 7) solvents; |
| Kenneth E. Freedland, PhD | 1) psychiatric comorbidity in coronary heart disease and congestive heart failure; 2) cognitive-behavioral treatment of depression and anxiety; 3) role and treatment of mental stress in coronary disease; |
| Anne L. Glowinski, MD, MPE | 1) genetic epidemiology of adolescent depression & suicidality; 2) parental alcoholism as a model of high risk g-e interplay; 3) medical education; 4) Improvement of community systems of care for youth psychopathology treatment and prevention; |
| Alison M. Goate, DPhil | 1) Molecular genetics of nicotine dependence; 2) Molecular genetics of Alzheimer's disease (AD) and other dementias; 3) Molecular genetics of alcoholism; 4) CSF and imaging biomarkers as endophenotypes for genetics of AD risk; 5) Functional studies to uncover disease mechanism; |
| Richard Grucza, PhD | 1) Genetic and environmental determinants of alcohol and other drug dependence among African-Amerians, and related health disparaties; 2) Early onset substance use as a risk factor for substance use disorders; 3) Interaractions between early substance use and molecular-genetic risk factors for substance use disorders; 4) Relationship between personality and substance use disorders; |
| Sarah Hartz, MD | 1) Genetic studies of psychiatric illnesses; |
| Dan W. Haupt, MD | 1) Metabolic effects of valproate augmentation of antipsychotic treatment; 2) Metabolic effects of antipsychotics in children; 3) Metabolic effects of antipsychotics in schizophrenia patients; 4) Psychopharmacology of schizophrenia; 5) Psychopharmacology of bipolar disorder; |
| Andrew C. Heath, DPhil | 1) alcoholism etiology and consequences; 2) genetic studies of alcoholism, smoking, and drug dependence; 3) genetic studies of depression, suicidality and anxiety disorders; 4) genetic studies of personality and personality disorder; 5) methodological research in genetic epidemiology; 6) genetic studies of child and adolescent psychopathology; |
| Tamara Hershey, PhD | 1) neural underpinnings of cognitive dysfunction in diseases relevant to dopamine and the basal ganglia; 2) effects of metabolic insults such as hypoglycemia on the brain and cognitive function; |
| Barry A. Hong, PhD, FAACP | 1) psychological and psychiatric aspects of chronic illness in particular renal failure, liver disease; 2) behavior effecting organ donation; 3) disaster research and training; 4) follow-up studies of living donors; 5) functional pain in IBS and chronic bladder pain; |
| Yukitoshi Izumi, MD, PhD | 1) LTP: memory mechanisms related with development, aging and neuronal disorders such as hypoglycemia and anoxia; 2) experimental neuropathology with brain slices and retinal preparations; relationship between excitotoxicity and energy deficiency; |
| Michael R. Jarvis, MD, PhD | 1) maintenance electroconvulsive therapy; 2) psychopharmacology; 3) emergency and inpatient psychiatry; 4) psychiatric education; |
| Eric Lenze, MD | 1) NIMH R01, Pharmacotherapy of late life Generalized Anxiety Disorder; 2) NIMH R01, Risk genes for late life depression after hip fracture; 3) submitted NIMH R01: CBT augmentation of SSRI in late life Generalized Anxiety Disorder; 4) NIMH R01: aripiprazole augmentation of antidepressants for treatment-resistant depression; 5) submitted NIMH R34: enhanced medical rehabilitation (PT and OT) for late-life depression; 6) pilot study: assessing and treating attention biases in anxiety disorders (collaborator: Tom Rodebaugh, Ph.D., Dept of Psychology); 7) fMRI study of depression treatment with SSRI vs CBT (PI: Yvette Sheline, M.D.); 8) collaborative care for anxiety disorders in primary care (PI: Bruce Rollman, M.D., M.P.H., University of Pittsburgh); |
| Collins E. Lewis, MD | 1) alcoholism and comorbid disorders; 2) Vietnam veterans with PTSD; |
| Joan L. Luby, MD | 1) preschool mood disorders; 2) infant/preschool psychopathology and nosology; 3) social/emotional development of the infant and toddler; 4) treatment of childhood affective disorders; |
| Patrick J. Lustman, PhD | 1) examination of the interaction of mental and physical illness, including studies of the prevalence, course, and treatment of psychiatric illness in patients with diabetes mellitus and/or gastrointestinal disorders; |
| Pamela A.F. Madden, PhD | 1) genetic studies on nicotine use and dependence; 2) the relationship between genetic influences on smoking behavior, and genetic factors responsible for the use and dependence on other substances (using alcohol as a model system); 3) genetic studies of possible mediators of genetic influence on cigarette use and the development of dependence on nicotine and other substances; |
| Daniel Mamah, MD, MPE | 1) High Dimensional Brain Mapping of Subcortical and Cortical Structures; 2) Diffusion Tensor Imaging (DTI) of White Matter Fiber Tracts; 3) Basic Pathophysiologic Mechanisms in Schizophrenia spectrum disorders; 4) Psychiatric Epidemiology; |
| Steven Mennerick, PhD | 1) physiology of glutamate and GABA signaling; 2) axonal physiology; 3) synaptic homeostasis and plasticity; |
| Krista Moulder, PhD | 1) synaptic plasticity and effects of neuronal activity; 2) mechanisms and modulation of neurotransmitter release; 3) neuronal survival; |
| Elliot C. Nelson, MD | 1) twin study of social phobia; 2) genetic epidemiology of childhood abuse; 3) case-control candidate gene study of opioid dependence; |
| Rosalind Joyce Neuman, PhD | 1) statistical and mathematical methods to localize genes underlying susceptibility to psychiatric illnesses; 2) using clustering methods to refine clinically heterogeneous phenotypes (in particular alcohol dependence) to more homogeneous forms; |
| John W. Newcomer, MD | 1) Metabolic and cardiovascular risk factors in individuals with neuropsychiatric disorders; 2) Metabolic effects of antipsychotics in children; 3) Regulation of memory performance in humans; 4) Therapies for neuropsychiatric disorders, particularly psychotic disorders; |
| Bruce Nock, PhD | 1) opiate abuse and stress; 2) morphine-stress-glucocorticoid interactions; 3) opiate use and susceptibility to posttraumatic stress disorder; |
| Petra Nowotny, PhD | 1) genotyping SNPs to find susceptibility genes for late-onset Alzheimer's disease; 2) functional effects of associated SNPs; 3) allele-specific gene expression of associated SNPs; |
| John W. Olney, MD | 1) role of excitatory transmitter dysfunction and associated neuronal degeneration (both excitotoxic and apoptotic) in both neurodevelopmental and adult-onset psychiatric disorders; |
| Michele Pergadia, PhD | 1) Genetic and environmental influences on nicotine withdrawal; 2) Genetic and environmental influences on personality; |
| Rumi Kato Price, PhD, MPE | 1) long-term effects of early truama, psychopathology, substance abuse, and trauma; 2) coping and protective factors mitigating suicidal risk; 3) deployment and reintegration mental health in military members; 4) human-genome epidemiology for substance use disorders and psychiatric comorbidity; 5) application of flexible computational techniques to epidemiologic data; |
| John R. Pruett, Jr., MD, PhD | 1) The development of visual attention to social and non-social stimuli in autistic and non-autistic individuals; 2) Functional connectivity MRI (fcMRI) studies of autism; 3) Visual form processing, as related to social perception and cognition; 4) Comparative cognition of reasoning and social functioning; |
| Wendy Reich, PhD | 1) Children of psychiatrically ill parents, especially parents with alcoholism, ASP, and bipolar disorder; 2) instrument development for the assessment of psychopathology in children four to eighteen, as well as the assessment of their home and social environment; 3) cross-cultural assessment; 4) behavior disorders in children; 5) development of training programs to teach use of child instruments; |
| Angela M. Reiersen, MD | 1) Autistic Traits and Motor Problems in Children with ADHD: I have been working on a project investigating autistic traits and motor problems in a population-based twin sample enriched for ADHD.; |
| John Rice, PhD | 1) method development in genetic epidemiology; 2) quantitative genetics; 3) genetics of affective disorders; 4) linkage analysis; 5) diagnostic stability/validity; 6) analysis of multivariate data, especially survival and logistic analyses; 7) analysis of whole genome association data; |
| Stephen L. Ristvedt, PhD | 1) symptom appraisal in physical disease, particularly psychological impediments and cues to seeking diagnosis for signs or symptoms; 2) personality and dispositional influences on health-related behaviors; |
| John W. Rohrbaugh, PhD | 1) brain electrical and psychophysiological studies of attention and cognition in normal subjects and in psychiatric patients; |
| Eugene H. Rubin, MD, PhD | 1) Depression and co-morbid medical illnesses; 2) Dementia; 3) Trends in psychiatric education; 4) Issues involving financial conflicts of interest at academic health centers; |
| Jeffrey F. Scherrer, PhD | 1) mind-body research; 2) veteran health issues; 3) comorbidity; 4) behavior genetics; 5) psychiatric epidemiology; |
| Yvette I. Sheline, MD | 1) structural brain changes associated with major depression; 2) PET and fMRI studies of brain function in major depression, particularly in relation to treatment response; |
| Erik J. Sirevaag, PhD | 1) alcohol and substance use and related disorders; |
| Catherine Woodstock Striley PhD, MSW, LCSW, ACSW, MPE | 1) racial/ethnic and gender disparities in health care (including mental health and substance abuse treatment); 2) barriers to mental health care and substance abuse treatment; 3) refugee and immigrant mental health; 4) psychiatric nosology and epidemiology; 5) research ethics; |
| Brian K. Suarez, PhD | 1) genetic epidemiology of psychiatric disorders where a major gene is implicated; 2) linkage studies of Mendelian diseases with emphasis on theoretical issues involved in mapping recessives in endogamous populations; |
| Dorothy Van Buren, PhD | 1) lifestyle interventions for youth with Type 2 diabetes and their families; 2) psychological treatments for binge eating disorder; 3) family based, behavioral treatments for pediatric obesity; 4) behavioral family therapy with adolescents with anorexia nervosa; |
| Richard D. Wetzel, PhD | 1) clinical and epidemiological studies of suicide; 2) clinical studies of cognitive functioning in psychiatric disorders; 3) research on cognitive therapy; 4) clinical neuropsychology; 5) validation of the TCI; 6) dissociative phenomena; 7) multiple personality; |
| Denise E. Wilfley, PhD | 1) causes, characterization, and treatment of obesity and eating disorders; 2) assessment and psychological treatments for eating disorders and obesity; 3) prevention of eating disorders and obesity in at-risk populations; 4) maintenance treatments for childhood obesity; 5) behavioral lifestyle intervention for obese children and their parents; 6) family-based and pharmacological interventions applied to the treatment of anorexia nervosa; |
| David F. Wozniak, PhD | 1) the role of excitatory amino acids in aging and development, Alzheimer;s disease, schizophrenia and other neuropsychiatric disorders; 2) the involvement of glutamate receptors in learning and memory, and neuronal injury and degeneration; 3) rodent models of developmental neuropsychiatric syndromes such as the fetal alcohol syndrome resulting from neonatal exposure to drugs of abuse and anesthetic agents; 4) behavioral phenotyping of mutant mice and the development of mouse models of human diseases; |
| Charles F. Zorumski, MD | 1) mechanisms regulating the actions of glutamate and GABA in the hippocampus; 2) short- and long-term synaptic plasticity in the hippocampus; 3) mechanisms involved in CNS neurodegeneration; |
